keyword
MENU ▼
Read by QxMD icon Read
search

rekhtman

keyword
https://www.readbyqxmd.com/read/27863924/successful-use-of-afatinib-after-erlotinib-induced-pneumonitis-in-a-patient-with-epidermal-growth-factor-receptor-mutant-lung-cancer
#1
Christopher D Jakubowski, Andrew J Plodkowski, Jason C Chang, Natasha Rekhtman, Afsheen Iqbal, Paul K Paik, Helena A Yu
No abstract text is available yet for this article.
October 26, 2016: Clinical Lung Cancer
https://www.readbyqxmd.com/read/27830957/health-related-quality-of-life-and-patient-reported-outcomes-of-ofatumumab-plus-fludarabine-and-cyclophosphamide-versus-fludarabine-and-cyclophosphamide-in-the-complement-2-trial-of-patients-with-relapsed-cll
#2
Tadeusz Robak, Krzysztof Warzocha, K Govind Babu, Yaroslav Kulyaba, Kazimierz Kuliczkowski, Kudrat Abdulkadyrov, Javier Loscertales, Iryna Kryachok, Janusz Kłoczko, Grygoriy Rekhtman, Wojciech Homenda, Jerzy Z Błoński, Astrid McKeown, Chai-Ni Chang, Vasudha Bal, Steen Lisby, Ira V Gupta, Sebastian Grosicki
Chronic lymphocytic leukemia (CLL) is an incurable disease. Quality of life during treatment and periods of subsequent remission is therefore vital. Health-related quality of life (HRQoL) was compared in relapsed CLL during and after treatment with ofatumumab combined with fludarabine and cyclophosphamide versus fludarabine and cyclophosphamide alone. The European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 v3 and QLQ-CLL16 were used to assess HRQoL in this open-label, phase 3 study. Improvements in prespecified domains of patient-reported outcomes (Global Health Status [GHS]/HRQoL and B symptom scores) were recorded in both treatment arms after three cycles and were sustained after 18 months of follow-up...
November 10, 2016: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/27825636/cabozantinib-in-patients-with-advanced-ret-rearranged-non-small-cell-lung-cancer-an-open-label-single-centre-phase-2-single-arm-trial
#3
Alexander Drilon, Natasha Rekhtman, Maria Arcila, Lu Wang, Andy Ni, Melanie Albano, Martine Van Voorthuysen, Romel Somwar, Roger S Smith, Joseph Montecalvo, Andrew Plodkowski, Michelle S Ginsberg, Gregory J Riely, Charles M Rudin, Marc Ladanyi, Mark G Kris
BACKGROUND: RET rearrangements are found in 1-2% of non-small-cell lung cancers. Cabozantinib is a multikinase inhibitor with activity against RET that produced a 10% overall response in unselected patients with lung cancers. To assess the activity of cabozantinib in patients with RET-rearranged lung cancers, we did a prospective phase 2 trial in this molecular subgroup. METHODS: We enrolled patients in this open-label, Simon two-stage, single-centre, phase 2, single-arm trial in the USA if they met the following criteria: metastatic or unresectable lung cancer harbouring a RET rearrangement, Karnofsky performance status higher than 70, and measurable disease...
November 4, 2016: Lancet Oncology
https://www.readbyqxmd.com/read/27819763/diagnosis-of-acute-cellular-rejection-and-antibody-mediated-rejection-on-lung-transplant-biopsies-a-perspective-from-members-of-the-pulmonary-pathology-society
#4
Anja C Roden, Dara L Aisner, Timothy C Allen, Marie Christine Aubry, Roberto J Barrios, Mary B Beasley, Philip T Cagle, Vera L Capelozzi, Sanja Dacic, Yimin Ge, Lida P Hariri, Sylvie Lantuejoul, Ross A Miller, Mari Mino-Kenudson, Andre L Moreira, Kirtee Raparia, Natasha Rekhtman, Lynette Sholl, Maxwell L Smith, Ming S Tsao, Marina Vivero, Yasushi Yatabe, Eunhee S Yi
CONTEXT: - The diagnosis and grading of acute cellular and antibody-mediated rejection (AMR) in lung allograft biopsies is important because rejection can lead to acute graft dysfunction and/or failure and may contribute to chronic graft failure. While acute cellular rejection is well defined histologically, no reproducible specific features of AMR are currently identified. Therefore, a combination of clinical features, serology, histopathology, and immunologic findings is suggested for the diagnosis of AMR...
November 7, 2016: Archives of Pathology & Laboratory Medicine
https://www.readbyqxmd.com/read/27788046/cytology-specimens-a-goldmine-for-molecular-testing
#5
Natasha Rekhtman, Sinchita Roy-Chowdhuri
No abstract text is available yet for this article.
November 2016: Archives of Pathology & Laboratory Medicine
https://www.readbyqxmd.com/read/27731748/ofatumumab-plus-fludarabine-and-cyclophosphamide-in-relapsed-chronic-lymphocytic-leukemia-results-from-the-complement-2-trial
#6
Tadeusz Robak, Krzysztof Warzocha, K Govind Babu, Yaroslav Kulyaba, Kazimierz Kuliczkowski, Kudrat Abdulkadyrov, Javier Loscertales, Iryna Kryachok, Janusz Kłoczko, Grygoriy Rekhtman, Wojciech Homenda, Jerzy Z Błoński, Astrid McKeown, Michele M Gorczyca, Jodi L Carey, Chai-Ni Chang, Steen Lisby, Ira V Gupta, Sebastian Grosicki
: In this multicenter, open-label, phase III study, patients with relapsed chronic lymphocytic leukemia (CLL) were randomized (1:1) to receive ofatumumab plus fludarabine and cyclophosphamide (OFA + FC) or FC alone; the primary endpoint being progression-free survival (PFS) assessed by an independent review committee (IRC). Between March 2009 and January 2012, 365 patients were randomized (OFA + FC: n = 183; FC: n = 182). Median IRC-assessed PFS was 28.9 months with OFA + FC versus 18...
October 12, 2016: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/27693541/spread-through-air-spaces-stas-is-an-independent-predictor-of-recurrence-and-lung-cancer-specific-death-in-squamous-cell-carcinoma
#7
Shaohua Lu, Kay See Tan, Kyuichi Kadota, Takashi Eguchi, Sarina Bains, Natasha Rekhtman, Prasad S Adusumilli, William D Travis
INTRODUCTION: Spread through air spaces (STAS) is a recently recognized pattern of invasion in lung adenocarcinoma, however, it has not yet been characterized in squamous cell carcinoma (SCC). METHODS: We reviewed 445 resected stage I-III lung SCC and investigated the clinical significance of STAS. Cumulative incidence of recurrence (CIR) and lung cancer-specific death (CID) were evaluated by competing risks analyses and overall survival (OS) by Cox models. RESULTS: Of total 445 patients, 336 (76%) were >65 years old...
September 28, 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/27646942/pneumonitis-in-patients-treated-with-anti-programmed-death-1-programmed-death-ligand-1-therapy
#8
Jarushka Naidoo, Xuan Wang, Kaitlin M Woo, Tunc Iyriboz, Darragh Halpenny, Jane Cunningham, Jamie E Chaft, Neil H Segal, Margaret K Callahan, Alexander M Lesokhin, Jonathan Rosenberg, Martin Voss, Charles M Rudin, Hira Rizvi, Xue Hou, Katherine Rodriguez, Melanie Albano, Ruth-Ann Gordon, Charles Leduc, Natasha Rekhtman, Bianca Harris, Alexander M Menzies, Alexander D Guminski, Matteo S Carlino, Benjamin Y Kong, Jedd D Wolchok, Michael A Postow, Georgina V Long, Matthew D Hellmann
PURPOSE: Pneumonitis is an uncommon but potentially fatal toxicity of anti-programmed death-1 (PD-1)/programmed death ligand 1 (PD-L1) monoclonal antibodies (mAbs). Clinical, radiologic, and pathologic features are poorly described. METHODS: Patients who received anti-PD-1/PD-L1 monotherapy or in combination with anti-cytotoxic T-cell lymphocyte-4 mAb were identified at two institutions (Memorial Sloan Kettering Cancer Center: advanced solid cancers, 2009 to 2014, and Melanoma Institute of Australia: melanomas only, 2013 to 2015)...
September 19, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/27588332/optimizing-workflows-and-processing-of-cytologic-samples-for-comprehensive-analysis-by-next-generation-sequencing-memorial-sloan-kettering-cancer-center-experience
#9
Shaozhou Ken Tian, J Keith Killian, Natasha Rekhtman, Ryma Benayed, Sumit Middha, Marc Ladanyi, Oscar Lin, Maria E Arcila
The value and suitability of cytology specimens for molecular diagnosis has been demonstrated by numerous studies. In practice, however, the success rates vary widely across institutions depending on the disease setting, institutional practices of acquisition, handling/processing, and testing methodologies. As the number of clinically relevant biomarkers continues to increase, more laboratories are turning to next-generation sequencing platforms for testing. Although amplicon-based next-generation sequencing assays, interrogating a limited genomic territory, can be performed with minimal input material, broader-based next-generation sequencing assays have higher DNA input requirements that may not be met if the small tissue samples are not acquired and handled appropriately...
September 2, 2016: Archives of Pathology & Laboratory Medicine
https://www.readbyqxmd.com/read/27552093/morphologic-accuracy-in-differentiating-primary-lung-adenocarcinoma-from-squamous-cell-carcinoma-in-cytology-specimens
#10
Maureen F Zakowski, Natasha Rekhtman, Manon Auger, Christine N Booth, Barbara Crothers, Mohiddean Ghofrani, Walid Khalbuss, Rodolfo Laucirica, Ann T Moriarty, Z Laura Tabatabai, Güliz A Barkan
CONTEXT: -The National Cancer Care Network and the combined College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology guidelines indicate that all lung adenocarcinomas (ADCs) should be tested for epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements. As the majority of patients present at a later stage, the subclassification and molecular analysis must be done on cytologic material...
October 2016: Archives of Pathology & Laboratory Medicine
https://www.readbyqxmd.com/read/27441784/transbronchial-lung-cryobiopsy-for-interstitial-lung-disease-diagnosis-a-perspective-from-members-of-the-pulmonary-pathology-society
#11
Kirtee Raparia, Dara L Aisner, Timothy Craig Allen, Mary Beth Beasley, Alain Borczuk, Philip T Cagle, Vera Capelozzi, Sanja Dacic, Lida P Hariri, Keith M Kerr, Sylvie Lantuejoul, Mari Mino-Kenudson, Natasha Rekhtman, Anja C Roden, Sinchita Roy-Chowdhuri, Lynette Sholl, Maxwell L Smith, Eric Thunnissen, Ming Sound Tsao, Yasushi Yatabe
Transbronchial lung cryobiopsy involves using a cryoprobe rather than forceps to obtain a bronchoscopic biopsy. Recent studies have shown that transbronchial cryobiopsy provides a larger specimen than conventional transbronchial forceps biopsy, and that the interobserver agreement in the interpretation of cryobiopsy specimens is comparable to that of a surgical lung biopsy. This is encouraging, and transbronchial lung cryobiopsy clearly has a role in the workup and diagnosis of interstitial lung diseases. However, very few patients who have been studied underwent both transbronchial lung cryobiopsy and surgical lung biopsy, and the available data suggest that the diagnostic accuracy of cryobiopsy may not be similar to that of surgical lung biopsy...
July 21, 2016: Archives of Pathology & Laboratory Medicine
https://www.readbyqxmd.com/read/27440269/parp-inhibitor-activity-correlates-with-slfn11-expression-and-demonstrates-synergy-with-temozolomide-in-small-cell-lung-cancer
#12
Benjamin H Lok, Eric E Gardner, Valentina E Schneeberger, Andy Ni, Patrice Desmeules, Natasha Rekhtman, Elisa de Stanchina, Beverly A Teicher, Nadeem Riaz, Simon N Powell, John T Poirier, Charles M Rudin
PURPOSE: PARP inhibitors (PARPi) are a novel class of small molecule therapeutics for small cell lung cancer (SCLC). Identification of predictors of response would advance our understanding, and guide clinical application, of this therapeutic strategy. EXPERIMENTAL DESIGN: Efficacy of PARP inhibitors olaparib, rucaparib, and veliparib, as well as etoposide and cisplatin in SCLC cell lines, and gene expression correlates, was analyzed using public datasets. HRD genomic scar scores were calculated from Affymetrix SNP 6...
July 20, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/27354471/an-expression-signature-as-an-aid-to-the-histologic-classification-of-non-small-cell-lung-cancer
#13
Luc Girard, Jaime Rodriguez-Canales, Carmen Behrens, Debrah M Thompson, Ihab W Botros, Hao Tang, Yang Xie, Natasha Rekhtman, William D Travis, Ignacio I Wistuba, John D Minna, Adi F Gazdar
PURPOSE: Most non-small cell lung cancers (NSCLCs) are now diagnosed from small specimens, and classification using standard pathology methods can be difficult. This is of clinical relevance as many therapy regimens and clinical trials are histology dependent. The purpose of this study was to develop an mRNA expression signature as an adjunct test for routine histo-pathological classification of NSCLCs. EXPERIMENTAL DESIGN: A microarray dataset of resected adenocarcinomas (ADC) and squamous cell carcinomas (SCC) was used as the learning set for an ADC-SCC signature...
June 28, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/27195432/liquid-biopsy-in-lung-cancer-a-perspective-from-members-of-the-pulmonary-pathology-society
#14
Lynette M Sholl, Dara L Aisner, Timothy Craig Allen, Mary Beth Beasley, Philip T Cagle, Vera L Capelozzi, Sanja Dacic, Lida P Hariri, Keith M Kerr, Sylvie Lantuejoul, Mari Mino-Kenudson, Kirtee Raparia, Natasha Rekhtman, Sinchita Roy-Chowdhuri, Eric Thunnissen, Ming Tsao, Marina Vivero, Yasushi Yatabe
Liquid biopsy has received extensive media coverage and has been called the holy grail of cancer detection. Attempts at circulating tumor cell and genetic material capture have been progressing for several years, and recent financially and technically feasible improvements of cell capture devices, plasma isolation techniques, and highly sensitive polymerase chain reaction- and sequencing-based methods have advanced the possibility of liquid biopsy of solid tumors. Although practical use of circulating RNA-based testing has been hindered by the need to fractionate blood to enrich for RNAs, the detection of circulating tumor cells has profited from advances in cell capture technology...
August 2016: Archives of Pathology & Laboratory Medicine
https://www.readbyqxmd.com/read/27081878/biomarker-testing-in-lung-carcinoma-cytology-specimens-a-perspective-from-members-of-the-pulmonary-pathology-society
#15
Sinchita Roy-Chowdhuri, Dara L Aisner, Timothy Craig Allen, Mary Beth Beasley, Alain Borczuk, Philip T Cagle, Vera Capelozzi, Sanja Dacic, Gilda da Cunha Santos, Lida P Hariri, Keith M Kerr, Sylvie Lantuejoul, Mari Mino-Kenudson, Andre Moreira, Kirtee Raparia, Natasha Rekhtman, Lynette Sholl, Eric Thunnissen, Ming Sound Tsao, Marina Vivero, Yasushi Yatabe
The advent of targeted therapy in lung cancer has heralded a paradigm shift in the practice of cytopathology with the need for accurately subtyping lung carcinoma, as well as providing adequate material for molecular studies, to help guide clinical and therapeutic decisions. The variety and versatility of cytologic-specimen preparations offer significant advantages to molecular testing; however, they frequently remain underused. Therefore, evaluating the utility and adequacy of cytologic specimens is critical, not only from a lung cancer diagnosis standpoint but also for the myriad ancillary studies that are necessary to provide appropriate clinical management...
April 15, 2016: Archives of Pathology & Laboratory Medicine
https://www.readbyqxmd.com/read/27056998/clinical-outcomes-with-pemetrexed-based-systemic-therapies-in-ret-rearranged-lung-cancers
#16
A Drilon, I Bergagnini, L Delasos, J Sabari, K M Woo, A Plodkowski, L Wang, M D Hellmann, P Joubert, C S Sima, R Smith, R Somwar, N Rekhtman, M Ladanyi, G J Riely, M G Kris
BACKGROUND: RET rearrangements are targetable, oncogenic lung cancer drivers. While previous series have shown durable clinical benefit with pemetrexed-based therapies in ALK- and ROS1-rearranged lung cancers, the benefits of pemetrexed-based treatments in patients with RET-rearranged lung cancers relative to other genomic subsets have not previously been explored. PATIENTS AND METHODS: A retrospective review of patients with pathologically confirmed stage IIIB/IV lung adenocarcinomas and evidence of a RET, ROS1, or ALK rearrangement, or a KRAS mutation was conducted...
July 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/26960398/next-generation-sequencing-of-pulmonary-large-cell-neuroendocrine-carcinoma-reveals-small-cell-carcinoma-like-and-non-small-cell-carcinoma-like-subsets
#17
Natasha Rekhtman, Maria C Pietanza, Matthew D Hellmann, Jarushka Naidoo, Arshi Arora, Helen Won, Darragh F Halpenny, Hangjun Wang, Shaozhou K Tian, Anya M Litvak, Paul K Paik, Alexander E Drilon, Nicholas Socci, John T Poirier, Ronglai Shen, Michael F Berger, Andre L Moreira, William D Travis, Charles M Rudin, Marc Ladanyi
PURPOSE: Pulmonary large cell neuroendocrine carcinoma (LCNEC) is a highly aggressive neoplasm, whose biologic relationship to small cell lung carcinoma (SCLC) versus non-SCLC (NSCLC) remains unclear, contributing to uncertainty regarding optimal clinical management. To clarify these relationships, we analyzed genomic alterations in LCNEC compared with other major lung carcinoma types. EXPERIMENTAL DESIGN: LCNEC (n = 45) tumor/normal pairs underwent targeted next-generation sequencing of 241 cancer genes by Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) platform and comprehensive histologic, immunohistochemical, and clinical analysis...
July 15, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/26898325/large-cell-neuroendocrine-carcinoma-of-the-lung-clinico-pathologic-features-treatment-and-outcomes
#18
Jarushka Naidoo, Maria L Santos-Zabala, Tunc Iyriboz, Kaitlin M Woo, Camelia S Sima, John J Fiore, Mark G Kris, Gregory J Riely, Piro Lito, Afsheen Iqbal, Stephen Veach, Stephanie Smith-Marrone, Inderpal S Sarkaria, Lee M Krug, Charles M Rudin, William D Travis, Natasha Rekhtman, Maria C Pietanza
BACKGROUND: Large cell neuroendocrine carcinoma (LCNEC) accounts for approximately 3% of lung cancers. Pathologic classification and optimal therapies are debated. We report the clinicopathologic features, treatment and survival of a series of patients with stage IV LCNEC. MATERIALS AND METHODS: Cases of pathologically-confirmed stage IV LCNEC evaluated at Memorial Sloan Kettering Cancer Center from 2006 to 2013 were identified. We collected demographic, treatment, and survival data...
January 21, 2016: Clinical Lung Cancer
https://www.readbyqxmd.com/read/26829312/small-cell-lung-cancer-can-recent-advances-in-biology-and-molecular-biology-be-translated-into-improved-outcomes
#19
REVIEW
Paul A Bunn, John D Minna, Alexander Augustyn, Adi F Gazdar, Youcef Ouadah, Mark A Krasnow, Anton Berns, Elisabeth Brambilla, Natasha Rekhtman, Pierre P Massion, Matthew Niederst, Martin Peifer, Jun Yokota, Ramaswamy Govindan, John T Poirier, Lauren A Byers, Murry W Wynes, David G McFadden, David MacPherson, Christine L Hann, Anna F Farago, Caroline Dive, Beverly A Teicher, Craig D Peacock, Jane E Johnson, Melanie H Cobb, Hans-Guido Wendel, David Spigel, Julien Sage, Ping Yang, M Catherine Pietanza, Lee M Krug, John Heymach, Peter Ujhazy, Caicun Zhou, Koichi Goto, Afshin Dowlati, Camilla Laulund Christensen, Keunchil Park, Lawrence H Einhorn, Martin J Edelman, Giuseppe Giaccone, David E Gerber, Ravi Salgia, Taofeek Owonikoko, Shakun Malik, Niki Karachaliou, David R Gandara, Ben J Slotman, Fiona Blackhall, Glenwood Goss, Roman Thomas, Charles M Rudin, Fred R Hirsch
No abstract text is available yet for this article.
April 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/26802447/the-complexity-of-diagnosing-latent-tuberculosis-infection-in-older-adults-in-long-term-care-facilities
#20
Natasha S Hochberg, Sergey Rekhtman, Julianne Burns, Lisa Ganley-Leal, Sina Helbig, Nathaniel S Watts, Gary H Brandeis, Jerrold J Ellner, C Robert Horsburgh
OBJECTIVES: In the USA, tuberculosis disease rates are highest in older adults. Diagnostic testing for latent tuberculosis infection (LTBI) has not been evaluated carefully in this group. The aim of this study was to define the relationship between tuberculin skin test (TST) results, T-SPOT.TB results, and T-cell responses to Mycobacterium tuberculosis antigens. METHODS: Long-term care facility residents with known prior TST results (positive or negative) were retested with TSTs and T-SPOT...
March 2016: International Journal of Infectious Diseases: IJID
keyword
keyword
48941
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"